T1	Outcomes 49 69	cytotoxicity-effects
T2	Outcomes 98 112	survival rates
T3	Outcomes 1519 1541	complete response (CR)
T4	Outcomes 1551 1572	partial response (PR)
T5	Outcomes 1583 1602	stable disease (SD)
T6	Outcomes 1613 1632	progressive disease
T7	Outcomes 1652 1678	overall response rate (RR)
T8	Outcomes 1769 1808	RR based on an intent-to-treat analysis
T9	Outcomes 1833 1848	Median survival
T10	Outcomes 1890 1915	granulocytopenia grade IV
T11	Outcomes 1926 1945	febrile neutropenia
T12	Outcomes 2037 2039	CR
T13	Outcomes 2048 2050	PR
T14	Outcomes 2061 2063	SD
T15	Outcomes 2076 2078	PD
T16	Outcomes 2095 2105	overall RR
T17	Outcomes 2174 2213	RR based on an intent-to-treat analysis
T18	Outcomes 2238 2253	Median survival
T19	Outcomes 2367 2394	RR was significantly higher
T20	Outcomes 2508 2562	clinical response making additional treatment feasible
T21	Outcomes 2567 2573	higher
T22	Outcomes 2611 2684	proportion of patients with a performance status 2+3 achieving a response
T23	Outcomes 2753 2782	significantly longer survival
T24	Outcomes 2818 2839	survival at 12 months
T25	Outcomes 2902 2948	Grade IV granulocytopenia and thrombocytopenia
T26	Outcomes 2954 2967	more frequent
T27	Outcomes 2989 3016	haematological side-effects
T28	Outcomes 3073 3085	cytotoxicity
